Literature DB >> 20679133

Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Mitali Chattopadhyay1, Carlos A Velazquez, April Pruski, Kamran V Nia, Khaled R Abdellatif, Larry K Keefer, Khosrow Kashfi.   

Abstract

Chronic inflammation is an underlying etiological factor in carcinogenesis; nonsteroidal anti-inflammatory drugs (NSAIDs) and their chemically modified NO-releasing prodrugs (NO-NSAIDs) are promising chemopreventive agents. The aim of this study was to conduct a head-to-head comparison between two NO-ASAs possessing different NO donor groups, an organic nitrate [3-nitrooxyphenyl acetylsalicylate (NO-ASA; NCX-4016)] and an N-diazeniumdiolate [NONO-ASA, O(2)- (acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA; CVM-01)], as antiulcerogenic, analgesic, anti-inflammatory, and antipyretic agents. All drugs were administered orally at equimolar doses. For antiulcerogenic study, 6 h after administration, the number and size of hemorrhagic lesions in stomachs from euthanized animals were counted. Tissue samples were frozen for prostaglandin E(2) (PGE(2)), superoxide dismutase (SOD), and malondialdehyde determination. For anti-inflammatory study, 1 h after drug administration, the volume of carrageenan-induced rat paw edemas was measured for 6 h. For antipyretic study, 1 h after dosing, fever was induced by intraperitoneal LPS, and body core temperatures measured for 5 h. For analgesic study, time-dependent analgesic effect of prodrugs was evaluated by carrageenan-induced hyperalgesia. Drugs were administered 30 min after carrageenan. NO-ASA and NONO-ASA were equipotent as analgesic and anti-inflammatory agents but were better than aspirin. Despite a drastic reduction of PGE(2) in stomach tissue, both prodrugs were devoid of gastric side effects. Lipid peroxidation induced by aspirin was higher than that observed by prodrugs. SOD activity induced by both prodrugs was similar, but approximately 2-fold higher than that induced by aspirin. CVM-01 is as effective as NCX-4016 in anti-inflammatory, analgesic, and antipyretic assays in vivo, and it showed an equivalent safety profile in the stomach. These results underscore the use of N-diazeniumdiolate moieties in drug design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679133      PMCID: PMC2967407          DOI: 10.1124/jpet.110.171017

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

Review 1.  COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.

Authors:  Garret A FitzGerald
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

2.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.

Authors:  B Cryer; M Feldman
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

3.  Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats.

Authors:  A Kurinets; L M Lichtenberger
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 4.  Epidemiology of NSAID-related gastroduodenal mucosal injury.

Authors:  C Aalykke; K Lauritsen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-10       Impact factor: 3.043

5.  Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis.

Authors:  S Kato; K Suzuki; H Ukawa; Y Komoike; K Takeuchi
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

6.  NO-aspirin: mechanism of action and gastrointestinal safety.

Authors:  S Fiorucci; P Del Soldato
Journal:  Dig Liver Dis       Date:  2003-05       Impact factor: 4.088

7.  The anti-ulcerogenic activity of the unripe plantain banana (Musa species).

Authors:  R Best; D A Lewis; N Nasser
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

8.  Nitric oxide donors increase mucus gel thickness in rat stomach.

Authors:  J F Brown; P J Hanson; B J Whittle
Journal:  Eur J Pharmacol       Date:  1992-11-13       Impact factor: 4.432

9.  Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells.

Authors:  J F Brown; A C Keates; P J Hanson; B J Whittle
Journal:  Am J Physiol       Date:  1993-09

10.  Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity.

Authors:  J L Wallace; B K Reuter; G Cirino
Journal:  J Gastroenterol Hepatol       Date:  1994       Impact factor: 4.029

View more
  13 in total

1.  NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Carlos A Velázquez-Martínez; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2015-09-21       Impact factor: 5.858

2.  JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.

Authors:  Niharika Nath; Mitali Chattopadhyay; Liliya Pospishil; Lucyna Z Cieciura; Satindra Goswami; Ravinder Kodela; Joseph E Saavedra; Larry K Keefer; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2010-08-24       Impact factor: 5.858

3.  Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide.

Authors:  Tareisha Dunlap; Sujeewa C Piyankarage; Gihani T Wijewickrama; Samer Abdul-Hay; Michael Vanni; Vladislav Litosh; Jia Luo; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2012-10-18       Impact factor: 3.739

Review 4.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

Review 5.  Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents.

Authors:  Austin Horton; Isaac T Schiefer
Journal:  Nitric Oxide       Date:  2019-01-11       Impact factor: 4.427

6.  Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Satindra Goswami; Zong Yuan Gan; Praveen P N Rao; Kamran V Nia; Carlos A Velázquez-Martínez; Khosrow Kashfi
Journal:  J Pharmacol Exp Ther       Date:  2013-01-24       Impact factor: 4.030

7.  Nitric Oxide-Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation.

Authors:  Khosrow Kashfi
Journal:  For Immunopathol Dis Therap       Date:  2012

8.  Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

Review 9.  Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.

Authors:  Amjad M Qandil
Journal:  Int J Mol Sci       Date:  2012-12-17       Impact factor: 5.923

10.  Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Pascale L Duvalsaint; Khosrow Kashfi
Journal:  Pharmacol Res Perspect       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.